Effects of interleukin-18 on natural killer cells: Costimulation of activation through Fc receptors for immunoglobulin

Shivani Srivastava, David Pelloso, Hailin Feng, Larry Voiles, David Lewis, Zdenka Haskova, Margaret Whitacre, Stephen Trulli, Yi Jiun Chen, John Toso, Zdenka L. Jonak, Hua Chen Chang, Michael Robertson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The antitumor activity of monoclonal antibodies is mediated by effector cells, such as natural killer (NK) cells, that express Fc receptors for immunoglobulin. Efficacy of monoclonal antibodies, including the CD20 antibody rituximab, could be improved by agents that augment the function of NK cells. Interleukin (IL)-18 is an immunostimulatory cytokine that has antitumor activity in preclinical models. The effects of IL-18 on NK cell function mediated through Fcγ receptors were examined. Human NK cells stimulated with immobilized IgG in vitro secreted IFN-γ as expected; such IFN-γ production was partially inhibited by blocking CD16 with monoclonal antibodies. IL-18 augmented IFN-γ production by NK cells stimulated with immobilized IgG or CD16 antibodies. NK cell IFN-γ production in response to immobilized IgG and/or IL-18 was inhibited by chemical inhibitors of Syk and several other kinases involved in CD16 signaling pathways. IL-18 augmented antibody-dependent cellular cytotoxicity (ADCC) of human NK cells against rituximab-coated Raji cells in vitro. IL-18 and rituximab acted synergistically to promote regression of human lymphoma xenografts in SCID mice. Inasmuch as IL-18 costimulates IFN-γ production and ADCC of NK cells activated through Fc receptors in vitro and augments antitumor activity of rituximab in vivo, it is an attractive cytokine to combine with monoclonal antibodies for treatment of human cancer.

Original languageEnglish
Pages (from-to)1073-1082
Number of pages10
JournalCancer Immunology Immunotherapy
Volume62
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Immunoglobulin Fc Fragments
Interleukin-18
Fc Receptors
Natural Killer Cells
Monoclonal Antibodies
Immunoglobulin G
Cytokines
SCID Mice
Antibodies
Heterografts
Antibody Formation
Lymphoma
Phosphotransferases
Rituximab

Keywords

  • Cancer immunotherapy
  • Cytokines
  • Lymphoma
  • Monoclonal antibodies
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Effects of interleukin-18 on natural killer cells : Costimulation of activation through Fc receptors for immunoglobulin. / Srivastava, Shivani; Pelloso, David; Feng, Hailin; Voiles, Larry; Lewis, David; Haskova, Zdenka; Whitacre, Margaret; Trulli, Stephen; Chen, Yi Jiun; Toso, John; Jonak, Zdenka L.; Chang, Hua Chen; Robertson, Michael.

In: Cancer Immunology Immunotherapy, Vol. 62, No. 6, 06.2013, p. 1073-1082.

Research output: Contribution to journalArticle

Srivastava, S, Pelloso, D, Feng, H, Voiles, L, Lewis, D, Haskova, Z, Whitacre, M, Trulli, S, Chen, YJ, Toso, J, Jonak, ZL, Chang, HC & Robertson, M 2013, 'Effects of interleukin-18 on natural killer cells: Costimulation of activation through Fc receptors for immunoglobulin', Cancer Immunology Immunotherapy, vol. 62, no. 6, pp. 1073-1082. https://doi.org/10.1007/s00262-013-1403-0
Srivastava, Shivani ; Pelloso, David ; Feng, Hailin ; Voiles, Larry ; Lewis, David ; Haskova, Zdenka ; Whitacre, Margaret ; Trulli, Stephen ; Chen, Yi Jiun ; Toso, John ; Jonak, Zdenka L. ; Chang, Hua Chen ; Robertson, Michael. / Effects of interleukin-18 on natural killer cells : Costimulation of activation through Fc receptors for immunoglobulin. In: Cancer Immunology Immunotherapy. 2013 ; Vol. 62, No. 6. pp. 1073-1082.
@article{7e5091a582c44832b8423ed35adf99d3,
title = "Effects of interleukin-18 on natural killer cells: Costimulation of activation through Fc receptors for immunoglobulin",
abstract = "The antitumor activity of monoclonal antibodies is mediated by effector cells, such as natural killer (NK) cells, that express Fc receptors for immunoglobulin. Efficacy of monoclonal antibodies, including the CD20 antibody rituximab, could be improved by agents that augment the function of NK cells. Interleukin (IL)-18 is an immunostimulatory cytokine that has antitumor activity in preclinical models. The effects of IL-18 on NK cell function mediated through Fcγ receptors were examined. Human NK cells stimulated with immobilized IgG in vitro secreted IFN-γ as expected; such IFN-γ production was partially inhibited by blocking CD16 with monoclonal antibodies. IL-18 augmented IFN-γ production by NK cells stimulated with immobilized IgG or CD16 antibodies. NK cell IFN-γ production in response to immobilized IgG and/or IL-18 was inhibited by chemical inhibitors of Syk and several other kinases involved in CD16 signaling pathways. IL-18 augmented antibody-dependent cellular cytotoxicity (ADCC) of human NK cells against rituximab-coated Raji cells in vitro. IL-18 and rituximab acted synergistically to promote regression of human lymphoma xenografts in SCID mice. Inasmuch as IL-18 costimulates IFN-γ production and ADCC of NK cells activated through Fc receptors in vitro and augments antitumor activity of rituximab in vivo, it is an attractive cytokine to combine with monoclonal antibodies for treatment of human cancer.",
keywords = "Cancer immunotherapy, Cytokines, Lymphoma, Monoclonal antibodies, Rituximab",
author = "Shivani Srivastava and David Pelloso and Hailin Feng and Larry Voiles and David Lewis and Zdenka Haskova and Margaret Whitacre and Stephen Trulli and Chen, {Yi Jiun} and John Toso and Jonak, {Zdenka L.} and Chang, {Hua Chen} and Michael Robertson",
year = "2013",
month = "6",
doi = "10.1007/s00262-013-1403-0",
language = "English",
volume = "62",
pages = "1073--1082",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Effects of interleukin-18 on natural killer cells

T2 - Costimulation of activation through Fc receptors for immunoglobulin

AU - Srivastava, Shivani

AU - Pelloso, David

AU - Feng, Hailin

AU - Voiles, Larry

AU - Lewis, David

AU - Haskova, Zdenka

AU - Whitacre, Margaret

AU - Trulli, Stephen

AU - Chen, Yi Jiun

AU - Toso, John

AU - Jonak, Zdenka L.

AU - Chang, Hua Chen

AU - Robertson, Michael

PY - 2013/6

Y1 - 2013/6

N2 - The antitumor activity of monoclonal antibodies is mediated by effector cells, such as natural killer (NK) cells, that express Fc receptors for immunoglobulin. Efficacy of monoclonal antibodies, including the CD20 antibody rituximab, could be improved by agents that augment the function of NK cells. Interleukin (IL)-18 is an immunostimulatory cytokine that has antitumor activity in preclinical models. The effects of IL-18 on NK cell function mediated through Fcγ receptors were examined. Human NK cells stimulated with immobilized IgG in vitro secreted IFN-γ as expected; such IFN-γ production was partially inhibited by blocking CD16 with monoclonal antibodies. IL-18 augmented IFN-γ production by NK cells stimulated with immobilized IgG or CD16 antibodies. NK cell IFN-γ production in response to immobilized IgG and/or IL-18 was inhibited by chemical inhibitors of Syk and several other kinases involved in CD16 signaling pathways. IL-18 augmented antibody-dependent cellular cytotoxicity (ADCC) of human NK cells against rituximab-coated Raji cells in vitro. IL-18 and rituximab acted synergistically to promote regression of human lymphoma xenografts in SCID mice. Inasmuch as IL-18 costimulates IFN-γ production and ADCC of NK cells activated through Fc receptors in vitro and augments antitumor activity of rituximab in vivo, it is an attractive cytokine to combine with monoclonal antibodies for treatment of human cancer.

AB - The antitumor activity of monoclonal antibodies is mediated by effector cells, such as natural killer (NK) cells, that express Fc receptors for immunoglobulin. Efficacy of monoclonal antibodies, including the CD20 antibody rituximab, could be improved by agents that augment the function of NK cells. Interleukin (IL)-18 is an immunostimulatory cytokine that has antitumor activity in preclinical models. The effects of IL-18 on NK cell function mediated through Fcγ receptors were examined. Human NK cells stimulated with immobilized IgG in vitro secreted IFN-γ as expected; such IFN-γ production was partially inhibited by blocking CD16 with monoclonal antibodies. IL-18 augmented IFN-γ production by NK cells stimulated with immobilized IgG or CD16 antibodies. NK cell IFN-γ production in response to immobilized IgG and/or IL-18 was inhibited by chemical inhibitors of Syk and several other kinases involved in CD16 signaling pathways. IL-18 augmented antibody-dependent cellular cytotoxicity (ADCC) of human NK cells against rituximab-coated Raji cells in vitro. IL-18 and rituximab acted synergistically to promote regression of human lymphoma xenografts in SCID mice. Inasmuch as IL-18 costimulates IFN-γ production and ADCC of NK cells activated through Fc receptors in vitro and augments antitumor activity of rituximab in vivo, it is an attractive cytokine to combine with monoclonal antibodies for treatment of human cancer.

KW - Cancer immunotherapy

KW - Cytokines

KW - Lymphoma

KW - Monoclonal antibodies

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84878830705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878830705&partnerID=8YFLogxK

U2 - 10.1007/s00262-013-1403-0

DO - 10.1007/s00262-013-1403-0

M3 - Article

C2 - 23604103

AN - SCOPUS:84878830705

VL - 62

SP - 1073

EP - 1082

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 6

ER -